ZCM
SBBP

Zebra Capital Management’s Strongbridge Biopharma plc. SBBP Stock Holding History

Zebra Capital Management’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-24,039
Closed -$66K – 169
2021
Q1 		$66K Buy
+24,039
New +$72.5K 0.07% 168

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Zebra Capital Management's SBBP Position: Q2 2021 in Review

Zebra Capital Management sold out of Strongbridge Biopharma plc. (SBBP) in Q2 2021, closing a stake of 24,039 shares — an estimated $66K sold.

Zebra Capital Management first reported a position in SBBP in Q1 2021 and held it in 1 quarter. The position peaked at $66K in Q1 2021. 59 funds tracked by Wall St. Rank hold SBBP as of Q2 2021.

  • Zebra Capital Management reported no remaining Strongbridge Biopharma plc. position as of Q2 2021 after selling out during the quarter.
  • Zebra Capital Management sold 24,039 Strongbridge Biopharma plc. shares in Q2 2021, an estimated $66K.
  • Zebra Capital Management first reported a position in Strongbridge Biopharma plc. in Q1 2021 and held it in 1 quarter.
  • Zebra Capital Management's Strongbridge Biopharma plc. position peaked at $66K in Q1 2021.
  • 59 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q2 2021.

Based on Zebra Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.